Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

Similar articles for PubMed (Select 21443771)


Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study.

Dauby N, De Wit S, Delforge M, Necsoi VC, Clumeck N.

J Int AIDS Soc. 2011 Mar 28;14:16. doi: 10.1186/1758-2652-14-16.


Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Møller H, Bower M.

J Clin Oncol. 2009 Feb 20;27(6):884-90. doi: 10.1200/JCO.2008.19.6626. Epub 2008 Dec 29.


HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.

Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

AIDS. 2008 Oct 18;22(16):2143-53. doi: 10.1097/QAD.0b013e3283112b77.


Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S; Swiss HIV Cohort.

J Natl Cancer Inst. 2005 Mar 16;97(6):425-32.


Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies.

Spagnuolo V, Galli L, Salpietro S, Gianotti N, Guffanti M, Cossarini F, Bigoloni A, Cinque P, Bossolasco S, Travi G, Fumagalli L, Lazzarin A, Castagna A.

Int J Cancer. 2012 Jun 15;130(12):2990-6. doi: 10.1002/ijc.26332. Epub 2011 Aug 30.


Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.

Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, Rasbach DA, Hulgan T, Sterling TR.

AIDS Patient Care STDS. 2010 May;24(5):279-86. doi: 10.1089/apc.2009.0283.


Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals.

Long JL, Engels EA, Moore RD, Gebo KA.

AIDS. 2008 Feb 19;22(4):489-96. doi: 10.1097/QAD.0b013e3282f47082.


Malignancies in HIV: pre- and post-highly active antiretroviral therapy.

Nutankalva L, Wutoh AK, McNeil J, Frederick WR, Reddy RB, Daftary M, Gentles A, Addae-Afoakwa K.

J Natl Med Assoc. 2008 Jul;100(7):817-20.


Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(6):931-9.


Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.

Bonnet F, Morlat P, Chêne G, Mercié P, Neau D, Chossat I, Decoin M, Djossou F, Beylot J, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2002 Jul;3(3):195-9.


Risk of human papillomavirus-associated cancers among persons with AIDS.

Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA.

J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30. doi: 10.1093/jnci/djp205. Epub 2009 Jul 31.


Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART.

Franzetti M, Adorni F, Parravicini C, Vergani B, Antinori S, Milazzo L, Galli M, Ridolfo AL.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):414-20. doi: 10.1097/QAI.0b013e318282a189.


Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.

Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang JM, Costagliola D.

J Clin Oncol. 2003 Sep 15;21(18):3447-53.


Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.


Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era.

Albini L, Calabresi A, Gotti D, Ferraresi A, Festa A, Donato F, Magoni M, Castelli F, Quiros-Roldan E.

AIDS Res Hum Retroviruses. 2013 Aug;29(8):1097-104. doi: 10.1089/AID.2012.0321. Epub 2013 May 9.


Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group.

BMC Infect Dis. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471.


Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression.

Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):203-8. doi: 10.1097/QAI.0b013e3181b033ab.


Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.

Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF.

Cancer. 2005 Oct 1;104(7):1505-11.


Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk